Open AccessThe use of epoetin alfa biosimilar in the anemia management in hemodialysis patients
Author(s) -
І. Dudar,
E. Krasjuk,
Y. Honchar,
Олена Лобода,
І. Shifris,
Viktor Krot,
V. Savchuk
Publication year - 2021
Publication title -
ukraïnsʹkij žurnal nefrologìï ta dìalìzu
Language(s) - English
Resource type - Journals
eISSN - 2616-7352
pISSN - 2304-0238
DOI - 10.31450/ukrjnd.3(71).2021.05
Subject(s) - medicine , hemodialysis , epoetin alfa , anemia , adverse effect , dialysis , biosimilar , erythropoietin , hemoglobin , surgery
Abstract. The present study aimed to evaluate the efficacy and safety of EMAVAIL (epoetin alfa) in the correction of anemia in hemodialysis patients.
Methods. A total of 36 patients undergoing regular hemodialysis were enrolled in this prospective study. Among the patients were 19 (53%) men and 17 (47%) women with severe anemia (hemoglobin (Hb) level ≤ 90 g/L). The mean patients' age was 48.41±1.82 years, an average dialysis vintage consisted of 42.38±10.41 months. All the patients had thrice-weekly hemodialysis sessions, with a mean duration of 12.6 ± 0.51 hours per week and Kt/V 1.27 ± 0.08. All the patients were treated with biosimilar of epoetin alfa EMAVAIL intravenously three times a week in adjustable doses. The follow-up period was 56 days.
Results. At the study entry, the mean Hb level in hemodialysis patients was 81.7±0,93 g/L. In 56 days of anemia treatment, the concentration of Hb increased to 109.17±1.75 g/L. Eventually, 32 (89%) patients achieved the target Hb level (110 g/L); 6 (17%) patients had adverse events (mild hypertension). There were no serious adverse events.
Conclusions. EMAVAIL is an effective and safe epoetin alfa biosimilar for anemia management in hemodialysis patients.